可溶性生物标志物可区分关节炎型银屑病患者和无关节炎银屑病患者。

Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis.

机构信息

Toronto Western Research Institute, Toronto Western Hospital, University Health Network, Toronto, ON, Canada.

出版信息

Rheumatology (Oxford). 2010 Jul;49(7):1399-405. doi: 10.1093/rheumatology/keq105. Epub 2010 Apr 25.

DOI:10.1093/rheumatology/keq105

PMID:20421218

Abstract

OBJECTIVE

Biomarkers may be helpful in screening patients with psoriasis for PsA. Our purpose was to identify serum biomarkers for psoriasis and PsA.

METHODS

Fifty-two patients with psoriasis (26 satisfying CASPAR classification criteria for PsA) and 26 healthy controls were recruited for our study. Patients with psoriasis and PsA were group matched for age, sex and psoriasis duration, whereas controls were matched for age and sex. Blood samples were drawn at the time of assessment and serum was analysed for the following: IL-12, IL-12p40, IL-17, TNF super family member 14 (TNFSF14), MMP-3, RANK ligand (RANKL), osteoprotegerin (OPG), cartilage oligomeric matrix protein (COMP), C-propeptide of Type II collagen (CPII), collagen fragment neoepitopes Col2-3/4(long mono) (C2C) and Col2-3/4(short) (C1-2C) and highly sensitive CRP (hsCRP). Data were analysed using logistic regression and receiver operating characteristic curves were plotted.

RESULTS

Fifty-two patients with psoriatic disease had a mean age of 46 years and psoriasis duration of 16.8 years. Compared with controls, increased serum levels of RANKL, TNFSF14, MMP-3 and COMP independently associated with psoriatic disease (P < 0.05). Twenty-six PsA patients (mean swollen and/or tender joint count 16, swollen joint count 5) were then compared with 26 patients who had psoriasis alone. Increased levels of hsCRP, OPG, MMP-3 and the CPII : C2C ratio were independently associated with PsA (P < 0.03).

CONCLUSION

This pilot study indicates that hsCRP, OPG, MMP-3 and the CPII : C2C ratio are biomarkers for PsA in patients with psoriasis.

摘要

目的

生物标志物有助于筛选银屑病患者是否患有银屑病关节炎（PsA）。本研究旨在确定银屑病和 PsA 的血清生物标志物。

方法

招募了 52 名银屑病患者（26 名符合 PsA 的 CASPAR 分类标准）和 26 名健康对照者。将银屑病和 PsA 患者按年龄、性别和银屑病病程进行组间匹配，而对照组则按年龄和性别进行匹配。在评估时抽取血液样本，并分析以下血清指标：白细胞介素 12（IL-12）、IL-12p40、IL-17、TNF 超家族成员 14（TNFSF14）、基质金属蛋白酶 3（MMP-3）、核因子κB 受体激活因子配体（RANKL）、骨保护素（OPG）、软骨寡聚基质蛋白（COMP）、Ⅱ型胶原 C 端肽（CPII）、Ⅱ型胶原 C 端肽（C1-2C）、Ⅱ型胶原 C 端肽（C2C）和高敏 C 反应蛋白（hsCRP）。采用逻辑回归分析数据，并绘制受试者工作特征曲线。

结果

52 名银屑病患者的平均年龄为 46 岁，银屑病病程为 16.8 年。与对照组相比，RANKL、TNFSF14、MMP-3 和 COMP 的血清水平升高与银屑病独立相关（P<0.05）。然后将 26 名 PsA 患者（平均肿胀和/或压痛关节数为 16，肿胀关节数为 5）与 26 名仅有银屑病的患者进行比较。hsCRP、OPG、MMP-3 和 CPII：C2C 比值升高与 PsA 独立相关（P<0.03）。